anti-doping raises a handful of sensible questions. This page answers them in order, starting with the fundamentals and moving to applications.
This page was last updated on 2026-05-20 and is reviewed periodically as new material appears.
Research has examined whether the peptide affects fat mass independently of growth hormone's other actions. Early animal studies suggested reductions in body fat, but species differences and small sample sizes limit interpretation. Human studies have generally been short and have not consistently shown large effects. Some trials measured body composition, lipid profiles, and safety parameters, but the overall picture is one of suggestive yet inconclusive metabolic activity. Findings vary across study populations and protocols.
A central uncertainty is whether observed metabolic changes translate into meaningful clinical benefits. Study designs vary in dose, duration, and participant characteristics, making comparisons difficult. Independent replication is limited, and the field lacks consensus on optimal endpoints or treatment duration. Ongoing or future studies may clarify mechanism and effect size, but current evidence does not establish a clear therapeutic role. Researchers often call for larger, longer, and better-controlled trials, while questions remain about which patient groups might respond.
Proposed mechanism focuses on lipolysis, the breakdown of stored triglycerides into free fatty acids and glycerol. AOD-9604 is thought to act on adipose tissue without stimulating appetite or affecting blood sugar in the same way as growth hormone. Laboratory studies report increased fat oxidation in some models. The precise receptor interactions and signaling pathways remain incompletely characterized. Researchers have proposed that the peptide may influence fat mobilization through pathways distinct from the full hormone.
AOD-9604 is a synthetic peptide whose structure corresponds to a C-terminal segment of human growth hormone. It is often described as hGH fragment 176-191, a 16-amino-acid sequence. The peptide was designed to isolate a region of hGH associated with fat metabolism while avoiding the full hormone's growth-promoting actions. Laboratory and commercial materials typically present it as a lyophilized powder for research use. Its identity is defined by amino acid sequence, not by a single brand.
The fragment includes residues that can form an internal disulfide bond between two cysteine positions. This structural feature can influence how the peptide folds and how stable it is in solution. AOD-9604 differs from full-length hGH in size and receptor interactions; it does not contain the entire growth hormone sequence. Published descriptions sometimes use slightly different residue numbering, so sequence information should be checked against primary sources. The molecule is small compared with intact hGH, which affects analytical detection and purification approaches.
| Property | Value | Notes |
|---|---|---|
| Chemical class | Synthetic peptide fragment | Not a full hormone |
| Molecular target | Proposed adipose tissue lipolysis | Receptor details uncertain |
| Typical research dose | Not established for clinical use | Doses vary across studies |
| Stability in solution | Limited; store cold | Avoid repeated freeze-thaw |
| Regulatory status | Not approved as a drug | Varies by country |
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
Identity and purity are usually assessed with reversed-phase high-performance liquid chromatography and mass spectrometry. Reversed-phase HPLC separates the peptide from related impurities and can estimate purity by ultraviolet absorbance, while mass spectrometry confirms the molecular mass and detects modifications. Peptide mapping, amino acid analysis, and disulfide mapping may be used when the sequence or disulfide arrangement must be verified. Because AOD9604 contains cysteine residues, oxidation and disulfide isomers are possible quality concerns in synthetic batches.
Quality varies among research-grade suppliers, so certificates of analysis and independent testing are important for verification. A typical certificate reports purity by HPLC, identity by mass spectrometry, appearance, and sometimes residual solvents or water content. AOD9604 is often sold as a research chemical not intended for human consumption, and labels can be inaccurate. Common misconceptions include treating the peptide as a form of growth hormone, assuming supplement status, or expecting approved-drug quality from unregulated products.
Regulatory interest in AOD-9604 increased after high-profile anti-doping cases involving peptide products. In some cases, the substance was supplied under alternative names or in compounded preparations, complicating traceability. Sports tribunals and anti-doping panels have discussed whether the peptide was explicitly banned at the time of use, leading to clarifications by the World Anti-Doping Agency. For consumers and researchers, the legal status can vary by jurisdiction, and products marketed as research chemicals may lack independent quality verification.
AOD-9604 is listed as a prohibited substance in sport by the World Anti-Doping Agency. It falls under the peptide hormones, growth factors, related substances, and mimetics class on the prohibited list. Anti-doping organizations treat its presence in an athlete's sample as an adverse finding unless a therapeutic use exemption applies. The prohibition reflects concerns about performance enhancement in competitive settings and the difficulty of distinguishing exogenous peptide use from endogenous hormone fragments.
Detection of AOD-9604 in biological samples relies on analytical techniques capable of distinguishing a small synthetic peptide from related endogenous sequences. Liquid chromatography coupled with tandem mass spectrometry is commonly used for confirmatory analysis. Sample preparation may involve immunoaffinity enrichment or solid-phase extraction to concentrate the peptide. Because the molecule is small and may be present at low concentrations, assay sensitivity and specificity are ongoing analytical challenges. Laboratories also validate methods against reference materials when available.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
A type of clinical trial in which only the doctor knows whether a patient is taking the standard treatment or the new treatment being tested. This helps prevent bias in treatment studies. (NCI) A study in which one party, either the investigator or participant, is unaware of what medication the participant is taking; also called single-masked study. (NLM) Source Data
=== Africa === The soybean first arrived in Africa via Egypt in 1857. Soya Meme (Baked Soya) is produced in the village called Bame Awudome near Ho, the capital of the Volta Region of Ghana, by the Ewe people of Southeastern Ghana and southern Togo.
analytical chemistry The branch of chemistry which studies and makes use of instruments and methods to separate, quantify, and identify chemical substances, both by classical wet chemistry techniques such as precipitation, extraction, distillation, and observational analysis, and by modern instrumental techniques such as chromatography, spectroscopy, and electrochemistry.
Sources: en.wikipedia.org
=== Inflammation === Neuroinflammation is considered a contributing mechanism in Parkinson's disease. Research has shown lasting activation of the brain's immune cells, microglia, in regions affected by the disease, suggesting that inflammation may play a role in the gradual loss of dopamine-producing neurons. While immune responses can be protective in the short term, chronic inflammation may damage neurons over time. Dopaminergic neurons appear to be particularly vulnerable under inflammatory conditions. The normal production and breakdown of dopamine already place these cells under higher stress than other neurons. When inflammation is present, this may increase the neurons' susceptibility to damage and speed up degeneration. Changes in dopamine signaling may then influence immune activity in the brain, creating a feedback loop to further worsen neuronal loss.
== Definition == Medication is a medicine or a chemical compound used to treat or cure illness. According to Encyclopædia Britannica, medication is "a substance used in treating a disease or relieving pain". As defined by the National Cancer Institute, dosage forms of medication can include tablets, capsules, liquids, creams, and patches. Medications can be administered in different ways, such as by mouth, by infusion into a vein, or by drops put into the ear or eye. A medication that does not contain an active ingredient and is used in research studies is called a placebo. In Europe, the term is "medicinal product", and it is defined by EU law as:
=== Electron spectroscopy === Penning ionization has been applied to Penning ionization electron spectroscopy (PIES) for gas chromatography detector in glow discharge by using the reaction for He* or Ne*. The kinetic energy of electron ejected is analyzed by the collisions between target (gas or solid) and metastable atoms by scanning the retarding field in a flight tube of the analyzer in the presence of a weak magnetic field. The electron produced by reaction has a kinetic energy E determined by:
Sources: en.wikipedia.org
=== Protein === MIA3 is a member of the MIA/OTOR family. The full-length protein spans 1,907 amino acids and localizes to the ER exit sites. It contains an N-terminal, SH3-like domain, two predicted transmembrane domains, a coiled-coiled domain, and a C-terminal, proline-rich domain. The SH3-like domain faces the ER lumen, where it can bind cargo for COPII carrier biogenesis, while the proline-rich domain faces the cytoplasm, where it can bind the COPII components Sec23/24. Of the two predicted transmembrane domains, only one actually crosses the membrane, whereas the second likely forms a hairpin structure that is only embedded in but not crossing the membrane.
Trails, known as Kiseki in Japan, is a series of science fantasy role-playing video games by Nihon Falcom and is part of the larger The Legend of Heroes franchise. Trails is set on the continent of Zemuria and features story arcs set across the nations of Liberl (Trails in the Sky), Crossbell (Trails from Zero and Trails to Azure), Erebonia (Trails of Cold Steel and Trails into Reverie), Calvard (Trails Through Daybreak and Trails Beyond the Horizon), and others. The series began in 2004, with 13 main entries and two remakes having been produced since. Trails primarily features turn-based combat, with spin-offs and more recent entries featuring more action gameplay. The series was conceived by Falcom to have the most ambitious narrative in gaming, with producer Toshihiro Kondo considering it his life's work. Trails games were released only in Asia until the 2010s, when English versions were published by Xseed Games and NIS America. The series had sold nine million copies by 2025. Manga, anime, and other canonical media have also been released. Trails is expected to end with its final entry by 2032.
=== In Morocco against homophobia === On June 2, 2015, she was part of Femen's first demonstration in Morocco, in front of the Hassan Tower in Rabat, where she kissed another activist topless. According to a press release, the action sought to "celebrate LGBT rights and denounce the injustice done to the homosexual community in Morocco". Seven hours after the protest, they were arrested, questioned for six hours, then expelled from the territory.
== Experimental chemistry == Experimental results of the chemistry of dubnium date back to 1974 and 1976. JINR researchers used a thermochromatographic system and concluded that the volatility of dubnium bromide was less than that of niobium bromide and about the same as that of hafnium bromide. It is not certain that the detected fission products confirmed that the parent was indeed element 105. These results may imply that dubnium behaves more like hafnium than niobium. The next studies on the chemistry of dubnium were conducted in 1988, in Berkeley. They examined whether the most stable oxidation state of dubnium in aqueous solution was +5. Dubnium was fumed twice and washed with concentrated nitric acid; sorption of dubnium on glass cover slips was then compared with that of the group 5 elements niobium and tantalum and the group 4 elements zirconium and hafnium produced under similar conditions. The group 5 elements are known to sorb on glass surfaces; the group 4 elements do not. Dubnium was confirmed as a group 5 member. Surprisingly, the behavior on extraction from mixed nitric and hydrofluoric acid solution into methyl isobutyl ketone differed between dubnium, tantalum, and niobium. Dubnium did not extract and its behavior resembled niobium more closely than tantalum, indicating that complexing behavior could not be predicted purely from simple extrapolations of trends within a group in the periodic table. This prompted further exploration of the chemical behavior of complexes of dubnium.
Sources: en.wikipedia.org
It is proposed to promote lipolysis in fat tissue, the breakdown of stored fat into fatty acids and glycerol. The detailed receptor and signaling mechanisms are not fully established.
Because it is a fragment rather than full growth hormone, it is generally described as lacking growth-promoting effects. Some studies suggest it may influence fat metabolism without the same systemic growth effects, though evidence is limited.
Human trials have measured body weight, fat mass, lean mass, lipid levels, and adverse events. Most have been small or short-term, so conclusions about long-term outcomes are limited.
It is a synthetic peptide based on a C-terminal fragment of human growth hormone. It is commonly referred to as hGH fragment 176-191 and is studied for metabolic effects rather than growth effects.